INCB3344CCR2 chemokine receptor antagonist CAS# 1262238-11-8 |
- INCB8761(PF-4136309)
Catalog No.:BCC1649
CAS No.:1341224-83-6
- RS 504393
Catalog No.:BCC1910
CAS No.:300816-15-3
- MK-0812
Catalog No.:BCC1755
CAS No.:624733-88-6
- INCB 3284 dimesylate
Catalog No.:BCC1646
CAS No.:887401-93-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1262238-11-8 | SDF | Download SDF |
| PubChem ID | 10008367 | Appearance | Powder |
| Formula | C29H34F3N3O6 | M.Wt | 577.6 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 240 mg/mL (415.52 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | N-[2-[[(3S,4S)-1-[4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide | ||
| SMILES | CCOC1CN(CC1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)C3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O | ||
| Standard InChIKey | MZEOSVPWMSEFPW-XYCDVDSTSA-N | ||
| Standard InChI | InChI=1S/C29H34F3N3O6/c1-2-39-25-16-35(21-8-10-28(38,11-9-21)19-6-7-23-24(13-19)41-17-40-23)15-22(25)34-26(36)14-33-27(37)18-4-3-5-20(12-18)29(30,31)32/h3-7,12-13,21-22,25,38H,2,8-11,14-17H2,1H3,(H,33,37)(H,34,36)/t21?,22-,25-,28?/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | INCB3344 is a potent CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.In Vitro:INCB3344 is a potent antagonist towards rat and cynomolgus CCR2 as well, displaying IC50 values of 7.3 and 16 nM in binding antagonism and 2.7 and 6.2 nM in antagonism of chemotaxis activity, respectively. INCB3344 is a selective hCCR2 antagonist, exhibiting IC50 values of more than 1 μM against a panel of >50 ion channels, transporters, chemokine receptors and other selected GPCRs. It is also a selective mCCR2 antagonist, showing IC50 values of >1 μM and >3 μM against murine CCR1 and murine CCR5, respectively, the two most homologous chemokine receptors to mCCR2[1]. Characterization of the pharmacological activity of INCB3344 is first evaluated by testing its ability to inhibit CCL2 binding to CCR2 in a whole cell binding assay using a murine monocyte cell line, WEHI-274.1 and 125I-labeled mCCL2 as a tracer. The binding IC50 of INCB3344 in this assay is determined to be 10±5 nM, and inhibition of >90% binding is observed at a concentration of 90 nM[2].In Vivo:When administered intravenously to CD-1 mice, INCB3344 exhibits a high clearance and a moderate volume of distribution, resulting in a short half life of 1 h. Despite its high clearance, however, good oral exposure is achieved, with an AUC at 2664 nM h at a dose of 10 mg/kg. The oral bioavailability is 47%. By comparison, slightly better oral exposure (AUC=3888 nM h) is obtained when administered orally to Balb/c mice at the same dose. This PK property, couple with its potent anti-mCCR2 activity and good selectivity, makes this compound suitable for model studies in rodents[1]. INCB3344 prevents deoxycorticosterone acetate (DOCA)/salt-induced changes in vascular expression of CCR2. In a separate series of experiments, CCR2 expression is elevated (≈1.5-fold higher) in aortas from mice that receive INCB3344 from days 7 to 21 of the DOCA/salt treatment period compare with sham animals; however, this level of CCR2 expression is significantly lower than that observed in the vehicle-treated group (P<0.05, n=6). Likewise, increased expression of its receptor ligand CCL2 in DOCA/salt-treated mice is blunted in mice receiving INCB3344 (P<0.05, n=6). By contrast, levels of CCL7, CCL8, and CCL12 are elevated to similar extents in DOCA/salt-treated mice receiving vehicle or INCB3344[3]. References: | |||||
| Kinase experiment [1]: | |
| Binding assays | WEHI 274.1 (murine monocytic cell line) cells were used in a whole cell binding assay. Cells (5×105) inRPMI 1640, 0.1% BSA, 20 mM HEPES were added to various concentrations of INCB3344 in RPMI 1640 followed immediately by the addition of 150 pM 125I-labeled mCCL2 (mouse CCL2(JE)) and incubated for 30 min at room temperature (RT). For the nonspecific control, 0.3 μM mCCL2 was added in place of INCB3344. Cells were then harvested through 1.2-μM polyvinylidene difluoride filters, the filters were airdried, and binding was determined by counting in a gamma counter. Antagonist activity is reported as the inhibitor concentration required for IC50 of specific binding. Specific binding is defined as the total binding minus the nonspecific binding and typically represents 97% of the total binding. |
| Cell experiment [1]: | |
| Cell lines | WEHI-274.1 cells |
| Preparation method | Dissolved in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
| Reacting condition | 0.3-300 nM; 6 min. |
| Applications | In WEHI-274.1 cells, INCB3344 inhibits monocyte chemotaxis with IC50 value of 10 nM using 30 nM mCCL2 as the agonist. INCB3344 blocks ERK phosphorylation in response to mCCL2 with IC50 value of 3-10 nM, which is mediated by CCR2 signaling. |
| Animal experiment [1]: | |
| Animal models | Female BALB/c mice (20 g) received i.p. injection of thioglycolate. |
| Dosage form | 30, 60, or 100 mg/kg BID; 48 h; administrated orally. |
| Application | INCB3344 dose-dependently reduces total cell number in the lavage fluid and inhibits monocyte influx by 36%, 55% and 73% at 30 mg/kg, 60 mg/kg and 100 mg/kg, respectively. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1]. Brodmerkel CM, Huber R, Covington M, et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344[J]. The Journal of Immunology, 2005, 175(8): 5370-5378. | |
INCB3344 Dilution Calculator
INCB3344 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7313 mL | 8.6565 mL | 17.313 mL | 34.626 mL | 43.2825 mL |
| 5 mM | 0.3463 mL | 1.7313 mL | 3.4626 mL | 6.9252 mL | 8.6565 mL |
| 10 mM | 0.1731 mL | 0.8657 mL | 1.7313 mL | 3.4626 mL | 4.3283 mL |
| 50 mM | 0.0346 mL | 0.1731 mL | 0.3463 mL | 0.6925 mL | 0.8657 mL |
| 100 mM | 0.0173 mL | 0.0866 mL | 0.1731 mL | 0.3463 mL | 0.4328 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
INCB3344 is a novel potent and selective antagonist of CCR2 receptor, which possesses an IC 50 of 10 nM for CCL2. [1]
CCR2 is a chemokine receptor mainly expressed on monocytes which acts as the key receptor in mediating their tissue influx in the context of immune-based inflammation. CCR2 is a G protein-coupled receptor (GPCR), whose ligands include the chemokines MCP family, including CCL2, CCL7, CCL8. These ligands bind CCR2 receptor with high affinity and elicit a chemotactic signal which leads to directed migration of the receptor-bearing cells. CCL2 has been shown to be relevant in high concentrations in various inflammatory lesions, implicating this chemokine as a physiologically important chemotactic signal for monocytes. [1]
Characterization of the pharmacological activity of INCB3344 was first evaluated by testing its ability to inhibit CCL2 binding to CCR2 in a whole cell binding assay using a murine monocyte cell line, WEHI-274.1 and 125I-labeled mCCL2 as a tracer. The binding IC 50 of INCB3344 in this assay was determined to be 10±5 nM, and inhibition greater than 90% binding was observed at a concentration of 90nM . The chemotaxis inhibitory activity of different concentrations of INCB3344 was evaluated using 30nM mCCL2 as the agonist. The result showed a similar potency to the binding assay. Selectivity of INCB3344 was evaluated against a panel of GPCRs including several human chemokine receptors using radioligand binding assays. Results from these studies demonstrate at least 100-fold selectivity of INCB3344 against all of the receptors tested. [1]
INCB3344 treatment results in a dose-dependent inhibition of macrophage influx in a mouse delayed-type hypersensitivity model. The histopathological analysis of tissues from the delayed-type hypersensitivity model illustrates that inhibitory activity of CCR2 leads to a substantial reduction in tissue inflammation. [1]
Reference:
[1]. Brodmerkel C M, Huber R, Covington M, et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344[J]. The Journal of Immunology, 2005, 175(8): 5370-5378.
- Agrimonolide 6-O-glucoside
Catalog No.:BCN6141
CAS No.:126223-29-8
- Ginsenoside Rg4
Catalog No.:BCN2713
CAS No.:126223-28-7
- LY2886721
Catalog No.:BCC3807
CAS No.:1262036-50-9
- Spiranthol A
Catalog No.:BCN7893
CAS No.:126192-35-6
- Icariside E5
Catalog No.:BCN6140
CAS No.:126176-79-2
- BAPTA-AM
Catalog No.:BCC5456
CAS No.:126150-97-8
- GNF179
Catalog No.:BCC5175
CAS No.:1261114-01-5
- Siamenoside I
Catalog No.:BCN2540
CAS No.:126105-12-2
- 11-Oxo-mogroside V
Catalog No.:BCN2509
CAS No.:126105-11-1
- Rubiyunnanin C
Catalog No.:BCN8045
CAS No.:1261030-04-9
- I-BET-762
Catalog No.:BCC4474
CAS No.:1260907-17-2
- 6-O-Methylcerevisterol
Catalog No.:BCN6139
CAS No.:126060-09-1
- Uralsaponin C
Catalog No.:BCN7906
CAS No.:1262326-46-4
- 24-Hydroxy-licoricesaponin A3
Catalog No.:BCN7896
CAS No.:1262326-47-5
- Uralsaponin D
Catalog No.:BCN7895
CAS No.:1262489-44-0
- (2R,3S)-Dihydrodehydroconiferyl alcohol
Catalog No.:BCN7886
CAS No.:126253-41-6
- Fumitremorgin B
Catalog No.:BCN6453
CAS No.:12626-17-4
- Assamicadine
Catalog No.:BCN1957
CAS No.:126260-96-6
- GS967
Catalog No.:BCC6401
CAS No.:1262618-39-2
- Benzoylmesaconine hydrochloride
Catalog No.:BCN5399
CAS No.:126266-38-4
- Penitrem A
Catalog No.:BCC7957
CAS No.:12627-35-9
- Trigonosin F
Catalog No.:BCN6403
CAS No.:1262842-73-8
- 25-Hydroxy VD2-D6
Catalog No.:BCC1305
CAS No.:1262843-46-8
- CCT241533
Catalog No.:BCC1462
CAS No.:1262849-73-9
Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344.[Pubmed:22205983]
PLoS One. 2011;6(12):e28933.
PURPOSE: To investigate the effect of an intravitreally administered CCR2 antagonist, INCB3344, on a mouse model of choroidal neovascularization (CNV). METHODS: CNV was induced by laser photocoagulation on Day 0 in wild type mice. INCB3344 or vehicle was administered intravitreally immediately after laser application. On Day 14, CNV areas were measured on retinal pigment epithelium (RPE)-choroid flat mounts and histopathologic examination was performed on 7 microm-thick sections. Macrophage infiltration was evaluated by immunohistochemistry on RPE-choroid flat mounts and quantified by flow cytometry on Day 3. Expression of vascular endothelial growth factor (VEGF) protein in RPE-choroid tissue was examined by immunohistochemistry and ELISA, VEGF mRNA in sorted macrophages in RPE-choroid tissue was examine by real-time PCR and expression of phosphorylated extracellular signal-regulated kinase (p-ERK 1/2) in RPE-choroid tissue was measured by Western blot analysis on Day 3. We also evaluated the efficacy of intravitreal INCB3344 to spontaneous CNV detected in Cu, Zn-superoxide dismutase (SOD1) deficient mice. Changes in CNV size were assessed between pre- and 1week post-INCB3344 or vehicle administration in fundus photography and fluorescence angiography (FA). RESULTS: The mean CNV area in INCB3344-treated mice decreased by 42.4% compared with the vehicle-treated control mice (p<0.001). INCB3344 treatment significantly inhibited macrophage infiltration into the laser-irradiated area (p<0.001), and suppressed the expression of VEGF protein (p = 0.012), VEGF mRNA in infiltrating macrophages (p<0.001) and the phosphorylation of ERK1/2 (p<0.001). The area of spontaneous CNV in Sod1(-)/(-) mice regressed by 70.35% in INCB3344-treated animals while no change was detected in vehicle-treated control mice (p<0.001). CONCLUSIONS: INCB3344 both inhibits newly forming CNV and regresses established CNV. Controlling inflammation by suppressing macrophage infiltration and angiogenic ability via the CCR-2/MCP-1 signal may be a useful therapeutic strategy for treating CNV associated with age-related macular degeneration.
Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.[Pubmed:21036044]
Bioorg Med Chem Lett. 2010 Dec 15;20(24):7473-8.
Rational design based on a pharmacophore of CCR2 antagonists reported in the literature identified lead compound 9a with potent inhibitory activity against human CCR2 (hCCR2) but moderate activity against murine CCR2 (mCCR2). Modification on 9a led to the discovery of a potent CCR2 antagonist 21 (INCB3344) with IC(50) values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity. INCB3344 exhibited >100-fold selectivity over other homologous chemokine receptors, a free fraction of 24% in human serum and 15% in mouse serum, and an oral bioavailability of 47% in mice, suitable as a tool compound for target validation in rodent models.
Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.[Pubmed:16210643]
J Immunol. 2005 Oct 15;175(8):5370-8.
This report describes the characterization of INCB3344, a novel, potent and selective small molecule antagonist of the mouse CCR2 receptor. The lack of rodent cross-reactivity inherent in the small molecule CCR2 antagonists discovered to date has precluded pharmacological studies of antagonists of this receptor and its therapeutic relevance. In vitro, INCB3344 inhibits the binding of CCL2 to mouse monocytes with nanomolar potency (IC(50) = 10 nM) and displays dose-dependent inhibition of CCL2-mediated functional responses such as ERK phosphorylation and chemotaxis with similar potency. Against a panel of G protein-coupled receptors that includes other CC chemokine receptors, INCB3344 is at least 100-fold selective for CCR2. INCB3344 possesses good oral bioavailability and systemic exposure in rodents that allows in vivo pharmacological studies. INCB3344 treatment results in a dose-dependent inhibition of macrophage influx in a mouse model of delayed-type hypersensitivity. The histopathological analysis of tissues from the delayed-type hypersensitivity model demonstrates that inhibition of CCR2 leads to a substantial reduction in tissue inflammation, suggesting that macrophages play an orchestrating role in immune-based inflammatory reactions. These results led to the investigation of INCB3344 in inflammatory disease models. We demonstrate that therapeutic dosing of INCB3344 significantly reduces disease in mice subjected to experimental autoimmune encephalomyelitis, a model of multiple sclerosis, as well as a rat model of inflammatory arthritis. In summary, we present the first report on the pharmacological characterization of a selective, potent and rodent-active small molecule CCR2 antagonist. These data support targeting this receptor for the treatment of chronic inflammatory diseases.
Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2.[Pubmed:19576173]
Biochem Biophys Res Commun. 2009 Sep 18;387(2):251-5.
The chemokine receptor 2 (CCR2) directs migration of monocytes and has been proposed to be a drug target for chronic inflammatory diseases. INCB3344 was first published as a small molecule nanomolar inhibitor of rodent CCR2. Here, we show that INCB3344 can also bind human CCR2 (hCCR2) with high affinity, having a dissociation constant (K(d)) of approximately 5nM. The binding of the compound to the receptor is rapid and reversible. INCB3344 potently inhibits hCCR2 binding of monocyte chemoattractant protein-1 (MCP-1) and MCP-1-induced signaling and function in hCCR2-expressing cells, including ERK phosphorylation and chemotaxis, and is competitive against MCP-1 in vitro. INCB3344 also blocks MCP-1 binding to monocytes in human whole blood, with potency consistent with in vitro studies. The whole blood binding assay described here can be used for monitoring pharmacodynamic activity of CCR2 antagonists in both preclinical models and in the clinic.
